-
Construction of cerebellar white matter profiles of cognitive and motor deficits after tumor resection
Time of Update: 2023-02-03
Study results The authors mapped the symptom maps of cognitive and motor deficits in children who survived cerebellar tumors to the structure map of cerebellar white matter, and observed that their cognitive, motor and executive dysfunction were associated with the superior foot nucleus (SCP), the deep cerebellar nucleus, including the intermediate nucleus (IN), the parietal nucleus (FN), the ventral medial dentate nucleus (DN), and the inferior vermis (VIIIa, VIIIB, IX, X cranial nerves).
-
Choice of surgical approach to meningioma in the petrous oblique region
Time of Update: 2023-02-03
of the Department of Neurosurgery at Autónoma de México, National University of Mexico City, Mexico, conducted a clinical study to propose a simple method to evaluate the applicability of RSA in resection of PCM based on the tumor characteristics of the posterior cranial fossa and the degree of displacement of the cerebellum, mid-foot and hemisphere.
-
Long-term follow-up of boron neutron capture therapy for recurrent malignant meningioma
Time of Update: 2023-02-03
Study results The researchers evaluated tumor size, overall survival (OS) and progression-free survival (PFS) after BNCT, and the reasons for treatment failure in 44 patients.
Study results The researchers evaluated tumor size, overall survival (OS) and progression-free survival (PFS) after BNCT, and the reasons for treatment failure in 44 patients.
-
CSF lymphocyte single-cell sequencing reveals immune signatures of brain metastases
Time of Update: 2023-02-03
Research methods Through the analysis of the immune characteristics of 50 cases of brain metastases, the authors found that T cells, NK cells, and tumor-associated macrophages (TAMs)/microglia exhibited highly variable and different phenotypic characteristics in different brain metastases, which can predict response to ICI treatment.
-
A three-year doubling of meningiomas is associated with postoperative recurrence
Time of Update: 2023-02-03
Research methods The authors retrospectively analyzed the clinical data of 269 meningioma patients who underwent surgery at the medical center from January 2007 to January 2021; These include WHO grade, MIB-1 SI, tumor location, degree of resection (Simpson grade), histological features, and recurrence.
-
Endoscopic transorbital approach resection of intraaxial lesions in the medial temporal lobe
Time of Update: 2023-02-03
Research methods The authors used 0° endoscopy to endoscopic dissection of four adult cadaver specimens to reach the medial temporal lobe region via orbital approach.
Research methods The authors used 0° endoscopy to endoscopic dissection of four adult cadaver specimens to reach the medial temporal lobe region via orbital approach.
-
Endoscopic transnasal or transorbital approach for lesions in the petrous apex
Time of Update: 2023-02-03
of the Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea, analyzed the efficacy of endoscopic transnasal (EEA) or transorbital approach (TOA) resection in patients with lesions in the rock apex area, and the results were published online in J Neurosurg in August 2021.
-
The sickle meningiomas were removed posterior to the cerebral sickle approach after the anterior wedge of the interhemispheric corpus callosum
Time of Update: 2023-02-03
Emrah Celtikci, Department of Neurosurgery, Pittsburgh Medical Center, Pennsylvania, USA, proposed another supratentorial approach for the resection of sickle meningioma, that is, the interhemispheric wedge anterior corpus callosum after the brain sickle approach through anatomical, imaging and clinical studies.
-
Choline kinase α2 acts as a protein kinase to promote the lipolysis of lipid droplets
Time of Update: 2023-02-03
Study results Finally, the authors conducted experiments on cell biology and nude mice and found that the cytostatic effect induced by PLIN2/3 phosphorylation defects is the result of lipolysis and decreased fatty acid production, rather than lipid accumulation.
-
Molecular basis and treatment of high-grade glioma in children
Time of Update: 2023-02-03
Conclusion of the study Finally, the authors note that the review explains the pathogenesis of high-grade gliomas in children from the perspective of genetic mutation and epigenetics; Taking specific mutations as the entry point for pHGG research can help improve clinical treatment decisions and is expected to realize individualized treatment of pHGG patients.
-
Relationship between body mass index and risk of glioma
Time of Update: 2023-02-03
Conclusion of the study In summary, there may be a nonlinear association between BMI and the risk of glioma in male patients.
Conclusion of the study In summary, there may be a nonlinear association between BMI and the risk of glioma in male patients.
-
Research Frontier Latest Discoveries! Mitomycin C The timing of bladder infusion may vary
Time of Update: 2023-02-02
Figure 4 Analysis of AEsConclusion of the studyIn patients with NMIBC, the use of neoadjuvant MMC intravesical instillation before TURBT appears to reduce the risk of tumor recurrence and progression, showing promising therapeutic efficacy and safety, and this preliminary analysis supports further studies of neoadjuvant MMC bladder instillation.
-
The first patient enrolled in the clinical trial of the innovative drug MDM2-p53 antagonist in the treatment of dedifferentiated liposarcoma in China
Time of Update: 2023-02-02
*For medical professionals onlyOn January 5, 2023, Boehringer Ingelheim announced that its innovative drug MDM2-p53 antagonist BI 907828 for the first-line treatment of dedifferentiated liposarcoma (D
-
Two combination therapies for lung cancer are released, significantly improving patient survival!
Time of Update: 2023-02-02
Significantly improves treatment outcomes 02 02 Not long ago, a phase 2 study in the United States showed that for metastatic non-small cell lung cancer with high expression of PD-L1, compared with PD-1 drug Zimberelimab alone, adding Domvanalimab and Etrumadenant can significantly improve treatment outcomes and patient survival.
-
Biomarkers associated with GBM electric field therapy
Time of Update: 2023-02-02
The results of this study showed that for GBM patients carrying PIK3CA-WT, EGFR-WT and NF1-WT, calculating MSS up to 3 points predicted a good treatment effect of TTFields.
-
Professor Zhou Caicun: 2022 important clinical research in the field of lung cancer
Time of Update: 2023-02-02
NEJM Medical Frontiers invited Professor Zhou Caicun from the Department of Oncology, Shanghai Pulmonary Hospital affiliated to Tongji University, to review important advances in the field of lung cancer in 2022, including perioperative treatment of NSCLC, and targeted therapy and immunotherapy progress of advanced NSCLC.
-
2023CASH| Pediatrics, Big Blood, Big Health: Parallel to the World Frontier to Cultivate Chinese Children's Hematology
Time of Update: 2023-02-02
Poke "Read Original" to watch the wonderful replay of the meetingAs the opening academic conference in this field, this sub-forum on pediatric hematology closely focuses on the theme of "big blood, big hygiene, big health", and accurately focuses on the breakthroughs in the diagnosis and treatment of various benign and malignant hematological diseases in children, which provides new ideas and brings new hope for the future development of children's hematology diseases and children.
-
Anti-tumor treatment for sudden hypercalcemia? The guide teaches you how to deal with it!
Time of Update: 2023-02-02
For adult patients with hypercalcaemia due to parathyroid carcinoma, if intravenous bisphosphonate or denosumab therapy is not adequately controlled, it is recommended to add calcimimetic compared with treatment without calcimimetic.
-
FDA Approval Annual Inventory (Part I) Digestive System Oncology
Time of Update: 2023-02-02
Tremelimumab and durvalumab are approvedindications7FDA approves capecitabine for drug label updates01 May 27,2022The FDA approved nivolumab in combination with fluoropyrimidine and platinum-based chemotherapy, and nivolumab plus ipilimumab as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC).
-
Chinese and Western Huayin Tumor Guards Your Dawn: Traditional Chinese medicine adjuvant therapy has multiple advantages of anti-tumor and anti-hepatitis B virus, escorting patients after liver cancer surgery
Time of Update: 2023-02-02
”Liver cancer in China is mostly caused by hepatitis,Some Chinese medicines have both anti-tumor and anti-hepatitis B virus effects, and the advantages of preventing recurrence are prominentHow to reasonably choose postoperative adjuvant treatment to reduce the risk of postoperative recurrence and prolong survival has become a hot spot and difficult point in clinical practice.
